References

1. Prausnitz, M.R.; Mitragotri, S.; Langer, R. Current status and future potential of transdermal drug delivery. Nat. Rev. Drug Discov. 2004, 3, 115–124.
2. Naik, A.; Kalia, Y.N.; Guy, R.H. Transdermal drug delivery: Overcoming the skin’s barrier function. Pharm. Sci. Technol. Today 2000, 3, 318–326.
3. Langer, R. Drug delivery and targeting. Nature 1998, 392 (Suppl. 6679), 5–10.
4. Bos, J.D.; Meinardi, M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology: Viewpoint 2000, 9, 165–169.
5. Wiedersberg, S.; Guy, R.H. Transdermal drug delivery: 30+ years of war and still fighting! J. Control. Release 2014, 190, 150–156.
6. Trommer, H.; Neubert, R. Overcoming the stratum corneum: The modulation of skin penetration. Ski. Pharmacol. Physiol. 2006, 19, 106–121.
7. Elias, P.M.; Friend, D.S. The permeability barrier in mammalian epidermis. J. Cell Biol. 1975, 65, 180–191.
8. Wertz, P.W.; Swartzendruber, D.C.; Squier, C.A. Regional variation in the structure and permeability of oral mucosa and skin. Adv. Drug Deliv. Rev. 1993, 12, 1–12.
9. Iyer, R.; Mok, S.; Savkovic, S.; Turner, L.; Fraser, G.; Desai, R.; Jayadev, V.; Conway, A.; Handelsman, D. Pharmacokinetics of testosterone cream applied to scrotal skin. Andrology 2017, 5, 725–731.
10. Basaria, S.; Dobs, A.S. New modalities of transdermal testosterone replacement. Treat. Endocrinol. 2003, 2, 1–9.
11. Ibrahim, S.A. Spray-on transdermal drug delivery systems. Expert Opin. Drug Deliv. 2015, 12, 195–205.
12. Hadgraft, J.; Lane, M.E. Skin permeation: The years of enlightenment. Int. J. Pharm. 2005, 305, 2–12.
13. Baroli, B. Penetration of nanoparticles and nanomaterials in the skin: Fiction or reality? J. Pharm. Sci. 2010, 99, 21–50.
14. Castro, G.A.; Oréfice, R.L.; Vilela, J.M.; Andrade, M.S.; Ferreira, L.A. Development of a new solid lipid nanoparticle formulation containing retinoic acid for topical treatment of acne. J. Microencapsul. 2007, 24, 395–407.
15. Chourasia, R.; Jain, S.K. Drug targeting through pilosebaceous route. Curr. Drug Targets 2009, 10, 950–967.
16. Toll, R.; Jacobi, U.; Richter, H.; Lademann, J.; Schaefer, H.; Blume-Peytavi, U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J. Investig. Dermatol. 2004, 123, 168–176.
17. Roberts, M.S. Solute-vehicle-skin interactions in percutaneous absorption: The principles and the people. Ski. Pharmacol. Physiol. 2013, 26, 356–370.
18. Chu, K.A.; Yalkowsky, S.H. An interesting relationship between drug absorption and melting point. Int. J. Pharm. 2009, 373, 24–40.
19. Yang, R.; Wei, T.; Goldberg, H.; Wang, W.; Cullion, K.; Kohane, D.S. Getting drugs across biological barriers. Adv. Mater. 2017, 29, 1606596.
20. Pastore, M.N.; Kalia, Y.N.; Horstmann, M.; Roberts, M.S. Transdermal patches: History, development and pharmacology. Br. J. Pharmacol. 2015, 172, 2179–2209.
21. Clemons, M.; Danson, S.; Howell, A. Tamoxifen (‘Nolvadex’): A review: Antitumour treatment. Cancer Treat. Rev. 2002, 28, 165–180.
22. Jordan, V.C. Tamoxifen (ICI46, 474) as a targeted therapy to treat and prevent breast cancer. Br. J. Pharmacol. 2006, 147, S269–S276.
23. Cuzick, J.; Sestak, I.; Cawthorn, S.; Hamed, H.; Holli, K.; Howell, A.; Forbes, J.F.; Investigators, I.-I. Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015, 16, 67–75.
24. Waters, E.A.; Cronin, K.A.; Graubard, B.I.; Han, P.K.; Freedman, A.N. Prevalence of tamoxifen use for breast cancer chemoprevention among US women. Cancer Epidemiol. Prev. Biomark. 2010, 19, 443–446.
25. Brauch, H.; Schroth, W.; Goetz, M.P.; Mürdter, T.E.; Winter, S.; Ingle, J.N.; Schwab, M.; Eichelbaum, M. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J. Clin. Oncol. 2013, 31, 176.
26. Teft, W.A.; Gong, I.Y.; Dingle, B.; Potvin, K.; Younus, J.; Vandenberg, T.A.; Brackstone, M.; Perera, F.E.; Choi, Y.-H.; Zou, G. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res. Treat. 2013, 139, 95–105.
27. Lee, O.; Page, K.; Ivancic, D.; Helenowski, I.; Parini, V.; Sullivan, M.E.; Margenthaler, J.A.; Chatterton, R.T.; Jovanovic, B.; Dunn, B.K. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast. Clin. Cancer Res. 2014, 20, 3672–3682.
28. Helland, T.; Hagen, K.B.; Haugstøyl, M.E.; Kvaløy, J.T.; Lunde, S.; Lode, K.; Lind, R.A.; Gripsrud, B.H.; Jonsdottir, K.; Gjerde, J. Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Res. Treat. 2019, 177, 185–195.
29. Fontein, D.; Seynaeve, C.; Hadji, P.; Hille, E.; van de Water, W.; Putter, H.; Kranenbarg, E.; Hasenburg, A.; Paridaens, R.J.; Vannetzel, J.-M. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis. J. Clin. Oncol. 2013, 31, 2257–2264.
30. Pathan, I.B.; Setty, C.M. Enhancement of transdermal delivery of tamoxifen citrate using nanoemulsion vehicle. Int. J. Pharm. Tech. Res. 2011, 3, 287–297.
31. Lin, S.L.; Chan, W.P.; Choy, C.-S.; Leung, T.-K. Enhancement of transdermal delivery of indomethacin and tamoxifen by far-infrared ray-emitting ceramic material (Bioceramic): A pilot study. Transl. Med. 2013.
32. Lee, O.; Ivancic, D.; Chatterton, R.T., Jr.; Rademaker, A.W.; Khan, S.A. In vitro human skin permeation of endoxifen: Potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast. Breast Cancer: Targets Ther. 2011, 3, 61.
33. Yang, Y.; Pearson, R.M.; Lee, O.; Lee, C.W.; Chatterton, R.T., Jr.; Khan, S.A.; Hong, S. Dendron-Based Micelles for Topical Delivery of Endoxifen: A Potential Chemo-Preventive Medicine for Breast Cancer. Adv. Funct. Mater. 2014, 24, 2442–2449.
34. Ambekar, R.S.; Choudhary, M.; Kandasubramanian, B. Recent advances in dendrimer-based nanoplatform for cancer treatment: A review. Eur. Polym. J. 2020, 126, 109546.
35. Lin, Y.-L.; Chen, C.-H.; Wu, H.-Y.; Tsai, N.-M.; Jian, T.-Y.; Chang, Y.-C.; Lin, C.-H.; Wu, C.-H.; Hsu, F.-T.; Leung, T.K. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex. J. Nanobiotechnol. 2016, 14, 1–10.
36. Bhatnagar, A.S. The discovery and mechanism of action of letrozole. Breast Cancer Res. Treat. 2007, 105, 7–17.
37. Lønning, P.; Dowsett, M.; Powles, T. Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. J. Steroid Biochem. 1990, 35, 355–366.
38. Perez, E.A. The balance between risks and benefits: Long-term use of aromatase inhibitors. Eur. J. Cancer Suppl. 2006, 4, 16–25.
39. Chetrite, G.; Cortes-Prieto, J.; Philippe, J.; Wright, F.; Pasqualini, J. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 2000, 72, 23–27.
40. Li, L.; Xu, X.; Fang, L.; Liu, Y.; Sun, Y.; Wang, M.; Zhao, N.; He, Z. The transdermal patches for site-specific delivery of letrozole: A new option for breast cancer therapy. AAPS PharmSciTech 2010, 11, 1054–1057.
41. Li, L.; Fang, L.; Xu, X.; Liu, Y.; Sun, Y.; He, Z. Formulation and biopharmaceutical evaluation of a transdermal patch containing letrozole. Biopharm. Drug Dispos. 2010, 31, 138–149.
42. Maniyar, M.; Chakraborty, A.; Kokare, C. Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. J. Liposome Res. 2020, 30, 274–284.
43. Geisler, J. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole–of clinical importance? Br. J. Cancer 2011, 104, 1059–1066.
44. Xi, H.; Yang, Y.; Zhao, D.; Fang, L.; Sun, L.; Mu, L.; Liu, J.; Zhao, N.; Zhao, Y.; Zheng, N. Transdermal patches for site-specific delivery of anastrozole: In vitro and local tissue disposition evaluation. Int. J. Pharm. 2010, 391, 73–78.
45. Regenthal, R.; Voskanian, M.; Baumann, F.; Teichert, J.; Brätter, C.; Aigner, A.; Abraham, G. Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation. Drug Des. Dev. Ther. 2018, 12, 3653.
46. Mendes, G.D.; Hamamoto, D.; Ilha, J.; dos Santos Pereira, A.; De Nucci, G. Anastrozole quantification in human plasma by high-performance liquid chromatography coupled to photospray tandem mass spectrometry applied to pharmacokinetic studies. J. Chromatogr. B 2007, 850, 553–559.
47. An, X.; Tiwari, A.K.; Sun, Y.; Ding, P.-R.; Ashby, C.R., Jr.; Chen, Z.-S. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leuk. Res. 2010, 34, 1255–1268.
48. Waller, C.F. Imatinib mesylate. In Small Molecules in Hematology; Springer: Cham, Switzerland, 2018; pp. 1–27.
49. Das, M.; Shim, K.H.; An, S.S.A.; Yi, D.K. Review on gold nanoparticles and their applications. Toxicol. Environ. Health Sci. 2011, 3, 193–205.
50. Larese Filon, F.; Crosera, M.; Adami, G.; Bovenzi, M.; Rossi, F.; Maina, G. Human skin penetration of gold nanoparticles through intact and damaged skin. Nanotoxicology 2011, 5, 493–501.
51. Filon, F.L.; Crosera, M.; Timeus, E.; Adami, G.; Bovenzi, M.; Ponti, J.; Maina, G. Human skin penetration of cobalt nanoparticles through intact and damaged skin. Toxicol. In Vitro 2013, 27, 121–127.
52. Labala, S.; Mandapalli, P.K.; Kurumaddali, A.; Venuganti, V.V.K. Layer-by-layer polymer coated gold nanoparticles for topical delivery of imatinib mesylate to treat melanoma. Mol. Pharm. 2015, 12, 878–888.
53. Moghimi, S.M.; Symonds, P.; Murray, J.C.; Hunter, A.C.; Debska, G.; Szewczyk, A. A two-stage poly (ethylenimine)-mediated cytotoxicity: Implications for gene transfer/therapy. Mol. Ther. 2005, 11, 990–995.
54. Labala, S.; Jose, A.; Chawla, S.R.; Khan, M.S.; Bhatnagar, S.; Kulkarni, O.P.; Venuganti, V.V.K. Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles. Int. J. Pharm. 2017, 525, 407–417.
55. Bollag, G.; Tsai, J.; Zhang, J.; Zhang, C.; Ibrahim, P.; Nolop, K.; Hirth, P. Vemurafenib: The first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 2012, 11, 873–886.
56. Wellbrock, C.; Hurlstone, A. BRAF as therapeutic target in melanoma. Biochem. Pharmacol. 2010, 80, 561–567.
57. da Rocha Dias, S.; Salmonson, T.; van Zwieten-Boot, B.; Jonsson, B.; Marchetti, S.; Schellens, J.H.; Giuliani, R.; Pignatti, F. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur. J. Cancer 2013, 49, 1654–1661.
58. Spengler, E.K.; Kleiner, D.E.; Fontana, R.J. Vemurafenib-induced granulomatous hepatitis. Hepatology 2017, 65, 745–748.
59. Launay-Vacher, V.; Zimner-Rapuch, S.; Poulalhon, N.; Fraisse, T.; Garrigue, V.; Gosselin, M.; Amet, S.; Janus, N.; Deray, G. Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients. Cancer 2014, 120, 2158–2163.
60. Zou, L.; Ding, W.; Zhang, Y.; Cheng, S.; Li, F.; Ruan, R.; Wei, P.; Qiu, B. Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin. Biomaterials 2018, 182, 1–12.
61. Ruan, R.; Jin, P.; Zhang, L.; Wang, C.; Chen, C.; Ding, W.; Wen, L. Peptide-chaperone-directed transdermal protein delivery requires energy. Mol. Pharm. 2014, 11, 4015–4022.
62. Leman, J.; Dick, D.; Morton, C. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin. Exp. Dermatol. 2002, 27, 516–518.
63. Morton, C.; Szeimies, R.M.; Sidoroff, A.; Braathen, L. European guidelines for topical photodynamic therapy part 1: Treatment delivery and current indications–actinic keratoses, Bowen’s disease, basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 536–544.
64. Lopez, R.F.V.; Lange, N.; Guy, R.; Bentley, M.V.L.B. Photodynamic therapy of skin cancer: Controlled drug delivery of 5-ALA and its esters. Adv. Drug Deliv. Rev. 2004, 56, 77–94.
65. Chen, H.M.; Liu, C.M.; Yang, H.; Chou, H.Y.; Chiang, C.P.; Kuo, M.Y.P. 5-aminolevulinic acid induce apoptosis via NF-κB/JNK pathway in human oral cancer Ca9–22 cells. J. Oral Pathol. Med. 2011, 40, 483–489.
66. Pierre, M.B.R.; Tedesco, A.C.; Marchetti, J.M.; Bentley, M.V.L. Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: Preparation and in vitro permeation study. BMC Dermatol. 2001, 1, 1–6.
67. Lin, M.-W.; Huang, Y.-B.; Chen, C.-L.; Wu, P.-C.; Chou, C.-Y.; Wu, P.-C.; Hung, S.-Y. A formulation study of 5-aminolevulinic encapsulated in DPPC liposomes in melanoma treatment. Int. J. Med. Sci. 2016, 13, 483.
68. Touitou, E.; Dayan, N.; Bergelson, L.; Godin, B.; Eliaz, M. Ethosomes—novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J. Control. Release 2000, 65, 403–418.
69. Allegra, A.; Innao, V.; Russo, S.; Gerace, D.; Alonci, A.; Musolino, C. Anticancer activity of curcumin and its analogues: Preclinical and clinical studies. Cancer Investig. 2017, 35, 1–22.
70. Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 2003, 23, 363–398.
71. Liu, W.; Zhai, Y.; Heng, X.; Che, F.Y.; Chen, W.; Sun, D.; Zhai, G. Oral bioavailability of curcumin: Problems and advancements. J. Drug Target. 2016, 24, 694–702.
72. Lee, W.-H.; Loo, C.-Y.; Young, P.M.; Traini, D.; Mason, R.S.; Rohanizadeh, R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin. Drug Deliv. 2014, 11, 1183–1201.
73. Sun, Y.; Du, L.; Liu, Y.; Li, X.; Li, M.; Jin, Y.; Qian, X. Transdermal delivery of the in situ hydrogels of curcumin and its inclusion complexes of hydroxypropyl-β-cyclodextrin for melanoma treatment. Int. J. Pharm. 2014, 469, 31–39.
74. Jose, A.; Labala, S.; Venuganti, V.V.K. Co-delivery of curcumin and STAT3 siRNA using deformable cationic liposomes to treat skin cancer. J. Drug Target. 2017, 25, 330–341.
75. Kortylewski, M.; Jove, R.; Yu, H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 2005, 24, 315–327.
76. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009, 9, 798–809.
77. Kanasty, R.; Dorkin, J.R.; Vegas, A.; Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 2013, 12, 967–977.
78. Song, X.; Zhang, M.; Dai, E.; Luo, Y. Molecular targets of curcumin in breast cancer. Mol. Med. Rep. 2019, 19, 23–29.
79. Atlan, M.; Neman, J. Targeted transdermal delivery of curcumin for breast cancer prevention. Int. J. Environ. Res. Public Health 2019, 16, 4949.
80. Abdel-Hafez, S.M.; Hathout, R.M.; Sammour, O.A. Curcumin-loaded ultradeformable nanovesicles as a potential delivery system for breast cancer therapy. Colloids Surf. B Biointerfaces 2018, 167, 63–72.
81. Pushpalatha, R.; Selvamuthukumar, S.; Kilimozhi, D. Cyclodextrin nanosponge based hydrogel for the transdermal co-delivery of curcumin and resveratrol: Development, optimization, in vitro and ex vivo evaluation. J. Drug Deliv. Sci. Technol. 2019, 52, 55–64.
82. Tian, B.; Liu, J. Resveratrol: A review of plant sources, synthesis, stability, modification and food application. J. Sci. Food Agric. 2020, 100, 1392–1404.
83. Carter, L.G.; D’Orazio, J.A.; Pearson, K.J. Resveratrol and cancer: Focus on in vivo evidence. Endocr. Relat. Cancer 2014, 21, R209–R225.
84. Walle, T. Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 9–15.
85. Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.; Fong, H.H.; Farnsworth, N.R.; Kinghorn, A.D.; Mehta, R.G.J.S. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275, 218–220.
86. Athar, M.; Back, J.H.; Tang, X.; Kim, K.H.; Kopelovich, L.; Bickers, D.R.; Kim, A.L. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224, 274–283.
87. Fontecave, M.; Lepoivre, M.; Elleingand, E.; Gerez, C.; Guittet, O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 1998, 421, 277–279.
88. Tsai, M.-J.; Lu, I.-J.; Fu, Y.-S.; Fang, Y.-P.; Huang, Y.-B.; Wu, P.-C. Nanocarriers enhance the transdermal bioavailability of resveratrol: In-vitro and in-vivo study. Colloids Surf. B Biointerfaces 2016, 148, 650–656.
89. Hu, C.; Wang, Q.; Ma, C.; Xia, Q. Non-aqueous self-double-emulsifying drug delivery system: A new approach to enhance resveratrol solubility for effective transdermal delivery. Colloids Surf. A Physicochem. Eng. Asp. 2016, 489, 360–369.
90. Qi, X.; Wang, L.; Zhu, J.; Hu, Z.; Zhang, J.J.I.j.o.p. Self-double-emulsifying drug delivery system (SDEDDS): A new way for oral delivery of drugs with high solubility and low permeability. Int. J. Pharm. 2011, 409, 245–251.
91. Park, S.N.; Jo, N.R.; Jeon, S.H. Chitosan-coated liposomes for enhanced skin permeation of resveratrol. J. Ind. Eng. Chem. 2014, 20, 1481–1485.
92. Pentek, T.; Newenhouse, E.; O’Brien, B.; Chauhan, A.S. Development of a topical resveratrol formulation for commercial applications using dendrimer nanotechnology. Molecules 2017, 22, 137.
93. Carletto, B.; Berton, J.; Ferreira, T.N.; Dalmolin, L.F.; Paludo, K.S.; Mainardes, R.M.; Farago, P.V.; Favero, G.M. Resveratrol-loaded nanocapsules inhibit murine melanoma tumor growth. Colloids Surf. B Biointerfaces 2016, 144, 65–72.
94. Palliyage, G.H.; Hussein, N.; Mimlitz, M.; Weeder, C.; Alnasser, M.H.A.; Singh, S.; Ekpenyong, A.; Tiwari, A.K.; Chauhan, H. Novel Curcumin-Resveratrol Solid Nanoparticles Synergistically Inhibit Proliferation of Melanoma Cells. Pharm. Res. 2021, 38, 851–871.